An interventional study of Ephedrine and Phenylephrine in Hypotension, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ephedrine in Hypotension — 4 open to participants now, 4 under way, none of them phase 3. Ephedrine · Hypotension.
Among the 22 studies testing ephedrine in Hypotension, this one is the 7th largest by planned enrollment, is one of 3 that started in 2019, is one of 6 with no phase, and was the 13th registered.
892 studies on the registry are indexed under Hypotension; 199 are open to participants now.
Browse Hypotension studies →4 of the 22 studies testing ephedrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 50+
Cairo University · Sites in Egypt
Ages 18–40 · Women only
Seoul National University Hospital
Ages up to 2
By country, each count listing its studies:
Ephedrine: first FDA approval 2016 (AKOVAZ). What it is approved for, and how studies give it, is on its page →
Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: 19 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1 · Phase 4 11
First in 2004; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 86 across 593 interventional studies indexed under Hypotension.
Median enrollment 120 across the 22 interventional studies. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital has 7 studies filed under Hypotension — fewer than ten, so there is no comparison to draw.
4 of the studies testing ephedrine in Hypotension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07379710Cairo UniversityNorepinephrine With Ephedrine Versus Norepinephrine Alone During Spinal Anesthesia for Cesarean Delivery | 2026-12 |
| NCT07722013Cairo UniversityIntermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension | 2026-12 |
| NCT04053478Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study | 2026-12 |
| NCT06257316Seoul National University HospitalAppropriate Dosage of Vasopressor in Neonates and Infants | 2027-02-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies testing ephedrine in Hypotension, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypotension is one of the most common adverse effects of spinal anesthesia for cesarean deliveries, affecting as many as 55-90% of mothers. Hypotension during cesarean deliveries can have detrimental effects on the mother and neonate. Various vasopressors, such as ephedrine, phenylephrine and more recently norepinephrine, have been used for the prevention and treatment of hypotension at cesarean deliveries.
Ephedrine was historically considered as the gold standard vasopressor for the management of hypotension during cesarean deliveries. This was based on studies in animal models that showed preserved uteroplacental circulation with ephedrine and not with phenylephrine. However, multiple studies in the past several decades have shown that phenylephrine compared with ephedrine results in a more favorable fetal acid-base status. Consequently, the use of phenylephrine for blood pressure management during cesarean deliveries increased. Recently, norepinephrine was introduced in the obstetrical practice for the management of hypotension at cesarean deliveries, due to its ability to maintain maternal cardiac output better than phenylephrine.
Studies have also investigated the use of vasopressin to limit hypotension during CD. There have been case reports of successful vasopressin usage to treat post-spinal hypotension after CD in patients with advanced idiopathic pulmonary arterial hypertension as well as severe mitral stenosis with pulmonary hypertension. Its effect was associated with hemodynamic stability without evidence of harm to the mother or child. However, much controversy still exists surrounding the choice of vasopressor in the obstetric population, in large part due to their varying efficacies, and maternal and fetal effects.
Vasopressors used for the treatment of hypotension during cesarean deliveries can have significant direct or indirect effects on the perfusion of uteroplacental and umbilical vessels. Reduction of uteroplacental perfusion and constriction of umbilical vessels can result in fetal acidosis, however, the mechanisms for these effects are unclear. The investigators hypothesize that ephedrine, phenylephrine and norepinephrine and vasopressin have variable effects on the contractility of pregnant myometrium and umbilical arteries due to their variable actions on adrenergic alpha (α) and beta (β) receptors, as well as vasopressin1 and vasopressin2 receptors located in these tissues.
One of the major concerns addressed in the literature is the risk of fetal acidosis related to the use of vasopressors, which varies according to the type of drug used. Since severe fetal acidosis is associated with a two- and four-fold increase in neonatal morbidity and mortality, respectively, it is important to understand the mechanism by which these medications may contribute to fetal acidosis.
It is well known that reduced uteroplacental blood flow can result in impaired fetal oxygenation and fetal acidosis. This can occur indirectly via compression of vessels due to myometrial contractions or directly by vasoactive effects on umbilical vessels. So far, no studies have directly explored the role of the aforementioned vasopressors on myometrial contractions and umbilical vessel vasoconstriction. An in-vitro approach in isolated tissues will eliminate many clinical confounding variables, allowing direct comparison of the drugs in a controlled environment, and providing insight into the contractile mechanisms responsible for their neonatal effects.
There is currently no consensus as to which vasopressor is best for the management of hypotension in obstetric patients and the mitigation of fetal acidosis. A survey of the members of the Society of Obstetric Anesthesia and Perinatology suggested significant variation in the practice of vasopressor use during cesarean deliveries. The evidence from animal studies contradicts the effects seen in human studies. This is possibly related to species differences in adrenergic receptor distribution, affinity to vasopressors, or placental transfer of vasopressors. It is well known that reduced uteroplacental blood flow can result in impaired fetal oxygenation and fetal acidosis. This can occur indirectly via compression of vessels due to myometrial contractions or directly by vasoactive effects on umbilical arteries. However, none of the studies so far have directly explored the role of the aforementioned vasopressors on myometrial contractions and umbilical artery vasoconstriction. An in-vitro approach in isolated tissues will eliminate many clinical confounding variables, allowing direct comparison of the drugs in a controlled environment, and providing insight into the contractile mechanisms responsible for their neonatal effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
Drug: Ephedrine
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
Drug: Phenylephrine
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
Drug: Norepinephrine
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
Drug: Vasopressin
The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
Drug: Ephedrine
The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
Drug: Phenylephrine
The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
Drug: Norepinephrine
The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
Drug: Vasopressin
The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
Drug: Ephedrine
The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
Drug: Phenylephrine
The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
Drug: Norepinephrine
The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
Drug: Vasopressin
Ephedrine in solution, at applicable concentrations based on literature
Phenylephrine, at applicable concentrations based on literature
Norepinephrine, at applicable concentrations based on literature
Vasopressin, at applicable concentrations based on literature
Motility index
Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude). Frequency and amplitude are secondary outcome measures as described below. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Amplitude of contraction
The maximum extent of uterine muscle and umbilical vessel contractions, measured in grams (g). The analysis is undertaken by attaching myometrial strips and umbilical vessel rings between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Frequency of contraction
The number of contractions in uterine muscle (myometrium) and umbilical vessel rings over 10 minutes, spontaneously and in response to an agonist. The analysis is undertaken by attaching myometrial strips and umbilical vessel rings between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Integrated area under response curve (AUC)
Time frame: 4 hours
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2019 (actual). Primary completion is estimated for Dec 2026, 89 months after the start.
Of 213 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 89 months is above that.
Counting every sponsor, half of 220 studies reached it within 12 months; a quarter within 6 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ephedrine · Phenylephrine · Norepinephrine · Arginine Vasopressin
Samuel Lunenfeld Research Institute, Mount Sinai Hospital →